Home
Scholarly Works
ASSESSMENT OF THE COST UTILITY OF PALIVIZUMAB FOR...
Conference

ASSESSMENT OF THE COST UTILITY OF PALIVIZUMAB FOR PREVENTING SEVERE RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION IN PRETERM INFANTS BORN 29-35 WEEKS' GESTATIONAL AGE IN THE PHILIPPINES

Authors

Del Rosario-Famadico S; Carbonell-Estrany X; Paes B; Tarride J-E; Rodgers-Gray B; Keary I; Fullarton J

Volume

28

Publisher

ELSEVIER SCIENCE INC

Publication Date

December 1, 2025

Conference proceedings

VALUE IN HEALTH

Issue

12

ISSN

1098-3015

Contact the Experts team